INVESTOR ALERT: Class Action Lawsuit Against Geron Corporation Announced by Law Offices of Howard G. Smith

  INVESTOR ALERT: Class Action Lawsuit Against Geron Corporation Announced by
  Law Offices of Howard G. Smith

Business Wire

BENSALEM, Pa. -- March 20, 2014

Law Offices of Howard G. Smith announces that a class action lawsuit has been
filed in the United States District Court for the Northern District of
California on behalf of all purchasers of the securities of Geron Corporation
(“Geron” or the “Company”) (NASDAQ:GERN) between June 16, 2013 and March 11,
2014, inclusive (the “Class Period”).

Geron is a clinical stage biopharmaceutical company developing first-in-class
therapies for cancer. The Company’s sole product candidate, imetelstat, is
designed to inhibit cancer cell replication in hematologic myeloid
malignancies such as myelofibrosis or acute myelogenous leukemia. The
Complaint alleges that throughout the Class Period defendants misrepresented
or failed to disclose that: (1) persistent low-grade liver function test (LFT)
abnormalities had been observed in the Phase 2 study of imetelstat in
essential thrombocythemia (ET) or polycythemia vera (PV) patients; (2) there
was a potential risk of chronic liver injury following long-term exposure to
imetelstat; and (3), as a result of the foregoing, defendants’ positive
statements about the Company and the prospects for imetelstat lacked any
reasonable basis and/or were materially false and misleading at all relevant
times.

On March 12, 2014, Geron disclosed that it had received verbal notice from the
U.S. Food and Drug Administration that Geron’s Investigational New Drug
application for imetelstat has been placed on full clinical hold – an order to
a trial sponsor to suspend an ongoing clinical trial or delay a proposed trial
– affecting all ongoing company-sponsored clinical trials, and that the FDA
expressed concern about whether the LFT abnormalities were reversible. As a
result, Geron informed investors that the clinical hold would affect the
remaining eight patients in the Company’s Phase 2 study in ET/PV and the
remaining two patients in the company’s Phase 2 study in multiple myeloma.
Also, the Company indicated that a planned Phase 2 clinical trial in
myelofibrosis would likely be delayed due to the clinical hold.

If you are a member of the Class described above, you have until May 13, 2014,
to move the Court to serve as lead plaintiff, if you meet certain legal
requirements. To be a member of the Class you need not take any action at this
time; you may retain counsel of your choice or take no action and remain an
absent member of the Class. If you wish to learn more about this action,
please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith,
3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at
(215) 638-4847, Toll Free at (888) 638-4847, or by email to
howardsmith@howardsmithlaw.com, or visit our website at
http://www.howardsmithlaw.com.

Contact:

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
(215) 638-4847
(888) 638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com
 
Press spacebar to pause and continue. Press esc to stop.